SmallCapReview.com has been a leading site for information on small cap stocks and penny stocks since 1999, to receive the free SmallCapReview newsletter visit http://www.smallcapreview.com.
Echo Therapeutics (OTCBB: ECTE) $2.00. Announced last week that the Company has completed the product development work for its Prelude SkinPrep System and now has the commercially ready product to be used in final clinical trials.
Echo anticipates that no further changes will be made to the Prelude SkinPrep System and that the current device will be the one used for sale, subject to FDA market clearance of the product. The final Prelude device replaces the prototype device used in earlier clinical trials and will be tested in the near-term in a study using LMX4 lidocaine cream which should form the basis for a 510-k filing with Ferndale Pharma Group for the enhanced delivery of lidocaine. The Company believes that the addressable market for enhanced, fast acting topical lidocaine exceeds $1 billion.
What They Do: Echo is developing the Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system for patients with diabetes and for use in hospital critical care units. Echo is also developing its needle-free Prelude SkinPrep System for transdermal drug delivery of a wide range of novel topical reformulations of widely-used, FDA-approved products.
Artificial Life (OTCBB: ALIF) $1.46. Today announced the launch of the official mobile game for the Starz Entertainment TV series "Spartacus: Blood and Sand", which premieres on Jan. 22, 2010. The Artificial Life game, for the iPhone and iPod touch platform, will retail at USD 4.99 on the Apple App Store. This is the second iPhone game collaboration between Artificial Life and Starz Media following PANDORUM, the official movie mobile game first released in September 2009.
What They Do: Artificial Life, Inc. (OTCBB: ALIF) is a public U.S. corporation headquartered in Los Angeles, with its production center in Hong Kong and additional offices in Berlin (EMEA headquarter) and Tokyo.
China Organic Agriculture (OTCBB: CNOA) $1.16. Announced on Friday after market close that it has appointed Mr. Bo Shan as its new Chief Financial Officer. Mr. Bo Shan, Chinese Certified Public Accountant, is 30 years old and is a graduate of the Hebei University of Economics and Business with a degree in Accounting. Prior joining the Company, Mr. Shan served as the senior accountant and deputy director in Zhonglei Certified Public Accountants Co., Ltd., a well known professional accounting firm in China, which offers a full range of professional services involving auditing, accounting, tax consultation, management consulting and capital verification.
What They Do: China Organic Agriculture is based in China and is primarily engaged in the acquisition, trading and distribution of agricultural products.
About SmallCapReview
Copyright SmallCapReview. SmallCapReview.com is a leading site for news on small-caps, penny stocks and microcaps. SmallCapReview has been compensated three thousand five hundred dollars by a third party Green Horseshoe for its services with regards to Echo Therapeutics. SmallCapReview has built a loyal opt-in following for their investor products by providing a newsletter at no cost, sent to subscribers, highlighting select stocks in play, to register visit http://www.smallcapreview.com.. To follow us on Twitter visit http://twitter.com/SmallCapReview.
